Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fostroxacitabine bralpamide
- Development stage
- Phase 2
- Lead developer
- Medivir
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fostroxacitabine bralpamide is a liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate, designed to deliver the active cytotoxic agent selectively to the liver. Upon oral administration, it is rapidly hydrolyzed in hepatocytes by carboxylesterase 1, generating high levels of troxacitabine triphosphate in the liver. This metabolite is incorporated into tumor cell DNA, leading to chain termination and inhibition of DNA synthesis, resulting in antitumor activity. The drug aims to maximize exposure within the liver while minimizing systemic toxicity and adverse effects on other organs. It is under development primarily for hepatocellular carcinoma (HCC) and other primary or secondary tumors affecting the liver[1][2][4][5][6].
- Brand names
- fostrox
- Other names
- Fostroxacitabine bralpamide [USAN]UNII-Q1I6YZ0NGFUNII-Q-1I6YZ0NGFUNII-Q 1I6YZ0NGFQ1I6YZ0NGFQ-1I6YZ0NGFQ 1I6YZ0NGF
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on Fostroxacitabine bralpamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fostroxacitabine bralpamide.